Literature DB >> 12507211

The preoperative assessment and postoperative surveillance of patients with colon and rectal cancer.

Walter E Longo1, Frank E Johnson.   

Abstract

Many advances have been made in the field of colorectal cancer follow-up since the pioneering efforts of Wangensteen and others with second-look operations in the 1950s. The understanding of the biology and natural history of colorectal malignancy has been advanced. Diagnostic methods for detection of recurrent disease have also advanced tremendously with CEA monitoring, immunoscintigraphy. CT, MRI, and PET imaging. As has been discussed in this article, however, no strategy of postoperative follow-up has been shown unequivocally to produce improved survival benefit or cure rate. It is quite possible that benefit will be shown, but well-controlled trials will be required. Cost considerations will likely prove important, because the rate of detection of curable disease will likely.be low. Quality of life issues will also be important in such trials. Better treatment and outcome ol recurrent disease would provide a strong rationale for vigorous postoperative surveillance. New recommendations are currently evolving [54]. Early diagnosis seems likely to enhance the curability of both local and distant relapses and second primary tumors. Furthermore, there may be a survival and quality of life advantage that results from the early institution of chemotherapy, even for those tumors found to be inoperable [55]. In devising a plan for follow-up in patients, it is important to recognize the anatomic and temporal patterns of recurrence as well as their relationships to the initial tumor staging. Although there is little proof that the identification of recurrent disease in follow-up programs increases the likelihood of resectability, cure, or prolonged survival, many physicians have witnessed successful treatment of recurrent colorectal cancer. These anecdotal experiences, the unproven belief that follow-up is beneficial, and traditions imparted during training are among the likely motivating factors for most physicians caring for colorectal cancer patients.

Entities:  

Mesh:

Year:  2002        PMID: 12507211     DOI: 10.1016/s0039-6109(02)00050-6

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  21 in total

1.  Self-expandable Metal Stent as a Bridge to Surgery for Colorectal Cancer: Safety and Oncological Outcomes.

Authors:  Marie Hanaoka; Taichi Ogo; Yudai Kawamura; Tomiyuki Miura; Tomoki Aburatani; Hitoshi Sugimoto; Naoaki Hoshino; Tsunehito Yauchi; Yoshinobu Nishioka; Tatsuyuki Kawano
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.

Authors:  Ming-Yii Huang; Chih-Hung Lin; Chun-Ming Huang; Hsiang-Lin Tsai; Ching-Wen Huang; Yung-Sung Yeh; Chee-Yin Chai; Jaw-Yuan Wang
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

3.  Loss of APAF-1 expression is associated with early recurrence in stage I, II, and III colorectal cancer.

Authors:  Byung Kyu Ahn; Sung Hoo Kim; Seung Sam Paik; Kang Hong Lee
Journal:  Langenbecks Arch Surg       Date:  2016-08-02       Impact factor: 3.445

4.  Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.

Authors:  Ming-Yii Huang; Joh-Jong Huang; Chun-Ming Huang; Chih-Hung Lin; Hsiang-Lin Tsai; Ching-Wen Huang; Chee-Yin Chai; Chia-Yang Lin; Jaw-Yuan Wang
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

5.  Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer.

Authors:  E Polat; U Duman; M Duman; A E Atici; E Reyhan; T Dalgic; E B Bostanci; S Yol
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

6.  The role of postoperative surveillance in colorectal cancer.

Authors:  Kerry Hammond; David A Margolin
Journal:  Clin Colon Rectal Surg       Date:  2007-08

7.  Predictive value of vascular endothelial growth factor overexpression in early relapse of colorectal cancer patients after curative resection.

Authors:  Hsiang-Lin Tsai; I-Ping Yang; Chih-Hung Lin; Chee-Yin Chai; Yu-Ho Huang; Chin-Fan Chen; Ming-Feng Hou; Chao-Hung Kuo; Suh-Hang Juo; Jaw-Yuan Wang
Journal:  Int J Colorectal Dis       Date:  2012-09-09       Impact factor: 2.571

8.  Lifestyle after colorectal cancer diagnosis in relation to recurrence and all-cause mortality.

Authors:  Moniek van Zutphen; Hendriek C Boshuizen; Marlou-Floor Kenkhuis; Evertine Wesselink; Anne J M R Geijsen; Johannes H W de Wilt; Henk K van Halteren; Ernst Jan Spillenaar Bilgen; Eric T P Keulen; Maryska L G Janssen-Heijnen; Stéphanie O Breukink; Martijn J L Bours; Dieuwertje E Kok; Renate M Winkels; Matty P Weijenberg; Ellen Kampman; Fränzel J B van Duijnhoven
Journal:  Am J Clin Nutr       Date:  2021-06-01       Impact factor: 7.045

9.  Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse.

Authors:  C-Y Lu; Y-H Uen; H-L Tsai; S-C Chuang; M-F Hou; D-C Wu; S-H Hank Juo; S-R Lin; J-Y Wang
Journal:  Br J Cancer       Date:  2011-02-22       Impact factor: 7.640

10.  The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse.

Authors:  I-Ping Yang; Hsiang-Lin Tsai; Ching-Wen Huang; Ming-Yii Huang; Ming-Feng Hou; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.